OR WAIT null SECS
© 2021 MJH Life Sciences and Pharmaceutical Executive. All rights reserved.
© 2021 MJH Life Sciences™ and Pharmaceutical Executive. All rights reserved.
When was the last time a big pharma’s shares massively outperformed a biotech index YTD? Hint: You likely weren’t around.
But could there be a shift in momentum?
A remarkable run indeed, but cost questions can’t be ignored.
What are the reasons behind the slump and what does the future hold?
Adding context to Pfizer’s orbit-busting, first-quarter earnings.
More capital gains and the potential strains for rest of 2021.
Amid vaccine heroics, its complex story may finally be resonating.
Dueling paths leave market fortunes uncertain.
Tone still set on the market catalysts to look for in 2021.
Vaccine strides, likely pricing impasse point to optimism for 2021.